Abstract
Lung, breast, and esophageal cancer represent three common malignancies with high incidence and mortality worldwide. The management of these tumors critically relies on radiotherapy as a major part of multi-modality care, and treatment-related toxicities, such as radiation-induced pneumonitis and/or lung fibrosis, are important dose limiting factors with direct impact on patient outcomes and quality of life. In this review, we summarize the current understanding of radiation-induced pneumonitis and pulmonary fibrosis, present predictive factors as well as recent diagnostic and therapeutic advances. Novel candidates for molecularly targeted approaches to prevent and/or treat radiation-induced pneumonitis and pulmonary fibrosis are discussed.
| Original language | English |
|---|---|
| Article number | 214 |
| Number of pages | 16 |
| Journal | Radiation Oncology |
| Volume | 15 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 10 Sept 2020 |
Keywords
- BREAST-CANCER PATIENTS
- CLINICAL-FEATURES
- CONCURRENT CHEMOTHERAPY
- EUROPEAN-ORGANIZATION
- HYPERFRACTIONATED RADIATION
- OBLITERANS ORGANIZING PNEUMONIA
- RISK-FACTORS
- STEM-CELLS
- THORACIC RADIOTHERAPY
- TUMOR VOLUME
Fingerprint
Dive into the research topics of 'Radiation-induced lung toxicity - cellular and molecular mechanisms of pathogenesis, management, and literature review'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver